Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Orelabrutinib Plus Lisaftoclax and Rituximab in Treatment-Naive, High-Risk Mantle Cell Lymphoma (MCL)
NCT07272499Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of orelabrutinib, lisaftoclax in mantle cell lymphoma (MCL), sponsored by Ruijin Hospital. Started Sep 2025; status: recruiting.
02
Drugs
orelabrutiniblisaftoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07272499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07272499.